Article

Focal therapy vs. surveillance for low-risk PCa

Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer?

Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer? UT spoke with Dr. Eggener at the 2019 annual meeting in Chicago.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC
January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke
Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
FDA logo
January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely
Catch up on all the notable drug and device approvals in urology over the past year.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.